325 related articles for article (PubMed ID: 15480434)
1. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell JA; Rampaul RS; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
Br J Cancer; 2004 Oct; 91(8):1532-42. PubMed ID: 15480434
[TBL] [Abstract][Full Text] [Related]
2. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.
Suo Z; Risberg B; Kalsson MG; Willman K; Tierens A; Skovlund E; Nesland JM
J Pathol; 2002 Jan; 196(1):17-25. PubMed ID: 11748637
[TBL] [Abstract][Full Text] [Related]
3. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
[TBL] [Abstract][Full Text] [Related]
4. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
[TBL] [Abstract][Full Text] [Related]
7. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
8. Significance of epidermal growth factor receptor expression in breast cancer.
Badovinac-Crnjevic T; Jakic-Razumovic J; Podolski P; Pleština S; Sarčević B; Munjas R; Vrbanec D
Med Oncol; 2011 Dec; 28 Suppl 1():S121-8. PubMed ID: 21104342
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
MacConmara M; O'Hanlon DM; Kiely MJ; Connolly Y; Jeffers M; Keane FB
Int J Oncol; 2002 Apr; 20(4):717-21. PubMed ID: 11894115
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma.
Vaidya P; Kawarada Y; Higashiguchi T; Yoshida T; Sakakura T; Yatani R
J Pathol; 1996 Feb; 178(2):140-5. PubMed ID: 8683379
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
[TBL] [Abstract][Full Text] [Related]
13. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
[TBL] [Abstract][Full Text] [Related]
14. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
Looi LM; Cheah PL
Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.
Langer R; Von Rahden BH; Nahrig J; Von Weyhern C; Reiter R; Feith M; Stein HJ; Siewert JR; Höfler H; Sarbia M
J Clin Pathol; 2006 Jun; 59(6):631-4. PubMed ID: 16731604
[TBL] [Abstract][Full Text] [Related]
17. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes.
Harłoziñska A; Bar JK; Wenderski R; Bebenek M
In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803
[TBL] [Abstract][Full Text] [Related]
18. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
19. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
20. c-erbB-4 protein expression in human breast cancer.
Kew TY; Bell JA; Pinder SE; Denley H; Srinivasan R; Gullick WJ; Nicholson RI; Blamey RW; Ellis IO
Br J Cancer; 2000 Mar; 82(6):1163-70. PubMed ID: 10735500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
